Summit Therapeutics PLC Sponsored ADR Stock

$24.56

6.33% yesterday

Nasdaq, Sep 18, 10:16 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$24.56

+23.11 1,588.67% 5Y

Nasdaq, Closing price Wed, Sep 18 2024

-1.66 6.33%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$17.79b
Enterprise Value	$17.57b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	91.19
Revenue growth (TTM) Revenue growth	-100.00%
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-144.53m
Free Cash Flow (TTM) Free Cash Flow	$-96.67m
Cash position	$325.79m
EPS (TTM) EPS	$-0.23
P/E forward	negative
Short interest	17.22%

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter Annually

Assets

Dec '23
Current assets	190 190
Cash	186 186
Claims	0.85 0.85
Inventories	- -
Other current assets Other current assets Current assets	2.62 2.62

Fixed assets	13 13
Property, plant and equipment	6.06 6.06
Financial assets	- -
Intangible Assets	1.89 1.89
Other fixed assets Other assets Fixed assets	5.28 5.28


Total Assets	203 203

Liabilities

Dec '23
Equity	78 78

Debt capital	125 125
Current liabilities	20 20
Non-current liabilities	105 105


Total Capital	203 203

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Positive

The Motley Fool

●

about 11 hours ago

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

Summit's cancer drug ivonescimab outperformed Keytruda in a recent clinical trial. The success of that trial led to a massive rally for the healthcare stock.

Positive

The Motley Fool

●

one day ago

Here's Why Everyone's Talking About Summit Therapeutics

A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy. In a phase 3 trial, treatment with ivonescimab reduced patients' risk of disease progression by 49% compared to Keytruda.

Positive

The Motley Fool

●

5 days ago

Why Summit Therapeutics Skyrocketed 123% This Week

Summit's Ivonescimab bested Keytruda in a phase 3 trial for lung cancer patients with the PD-L1 gene. Following the early-week stock spike, Summit raised over $200 million from investors.

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	105
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now